Bessemer Group
ALLO icon

Bessemer Group’s Allogene Therapeutics ALLO Stock Holding History

Bessemer Group’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-130
Closed -$4K – 1628
2019
Q1 		$4K Hold
130
– – ﹤0.01% 1617
2018
Q4 		$4K Buy
+130
New +$3.45K ﹤0.01% 1808

Other funds holding ALLO

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
VM
VV Manager Boston, Massachusetts $114M AUM 59.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bessemer Group's ALLO Position: Q2 2019 in Review

Bessemer Group sold out of Allogene Therapeutics (ALLO) in Q2 2019, closing a stake of 130 shares — an estimated $4K sold.

Bessemer Group first reported a position in ALLO in Q4 2018 and held it in 2 quarters. The position peaked at $4K in Q1 2019. 94 funds tracked by Wall St. Rank hold ALLO as of Q2 2019.

  • Bessemer Group reported no remaining Allogene Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Bessemer Group sold 130 Allogene Therapeutics shares in Q2 2019, an estimated $4K.
  • Bessemer Group first reported a position in Allogene Therapeutics in Q4 2018 and held it in 2 quarters.
  • Bessemer Group's Allogene Therapeutics position peaked at $4K in Q1 2019.
  • 94 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2019.

Based on Bessemer Group's 13F filing for Q2 2019, filed 19 Jul 2019.